Market Cap 12.77B
Revenue (ttm) 13.64B
Net Income (ttm) 746.80M
EPS (ttm) N/A
PE Ratio 16.94
Forward PE 13.18
Profit Margin 5.47%
Debt to Equity Ratio -22.49
Volume 586,295
Avg Vol 879,160
Day's Range N/A - N/A
Shares Out 64.20M
Stochastic %K 96%
Beta 0.84
Analysts Sell
Price Target $190.50

Company Profile

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administ...

Industry: Medical Care Facilities
Sector: Healthcare
Phone: 720 631 2100
Address:
2000 16th Street, Denver, United States
MikeyMcDermott
MikeyMcDermott Aug. 3 at 11:53 PM
$DVA crazy strong chart. those monthly bars straight up and new ATHs. can it continue after earnings?
0 · Reply
Noname2022
Noname2022 Aug. 3 at 9:09 PM
$CRMD $DVA $FMS $AKBA https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q2/FME_Q2_2026_Analyst_Presentation.pdf
1 · Reply
Noname2022
Noname2022 Aug. 3 at 8:28 PM
0 · Reply
k3vl4r
k3vl4r Aug. 3 at 4:45 PM
$DAVITA is about to get a surprise: kidney stone demand could be overheated before earnings. Thoughts? https://app.k3vl4r.com/blog/dva-davita-s-kidney-stones-why-the-dialysis-renaissance-might-be-priced?utm_source=social&utm_medium=social&utm_campaign=blog_publish $DVA #stocks #investing
0 · Reply
MaverikIT
MaverikIT Aug. 3 at 2:08 PM
$DVA +5.44 - do the give da --- to gp-l1 ? @trader365 @howardlindzon
0 · Reply
Noname2022
Noname2022 Aug. 2 at 1:06 PM
$CRMD $ICUI $DVA $FMS Clearguard HD: guessing DVA contract & best guess at access trends based on their marketing data (Fresenius uses both Clearguard HD & Defencath!) On the Q2 2024 call, ICU Medical said it had: “recently signed a multi-year committed agreement with a leading U.S. operator of dialysis clinics” Management said the agreement would expand its evidence base and help attract other dialysis operators. https://stockanalysis.com/stocks/icui/transcripts/192237-q2-2024/
0 · Reply
SparkyReturns
SparkyReturns Jul. 31 at 2:41 AM
$ICU I wonder how many hospitals are familiar with the Seastar SCD device and some affiliated doctors even trained with it, but are holding out until the SAVE registry goes away soon? For example, they are using the adult SCD at the Ronald Reagan Hospital in LA at UCLA, but the 18 bed pediatric wing is not in the SCD-PED study. However, if the SAVE registry requirements are dropped, will Ron Reagan UCLA Pediatric order 5 or 10 treatments so they have them on hand? If the FDA says it works, would it not be medical negligence not to use the new standard of care on a pediatric patient with AKI/Sepsis? I know the answer to that, and I wouldn't want to be that hospital if they didn't order the SCD-PED like stat. I predict there are 5-10 pediatric hospitals in this situation where if the SAVE Registry is dropped, we could have a flood of 25-100 orders overnight at $18,000 per treatment, or an extra $500K-$2M before we know it. GL! $FMS $DVA $BAX
4 · Reply
MaverikIT
MaverikIT Jul. 29 at 2:48 PM
@howardlindzon @Jblack500 @cynicaloptimist @BustaCapital @IsabellaDC @WAJeff @No_Face_character $DVA waving to another 52wk$ earlier
0 · Reply
Noname2022
Noname2022 Jul. 28 at 5:18 PM
$AKBA $DVA “There was no statistically significant difference between mortality rates with Vafseo versus ESA.” https://www.tipranks.com/news/the-fly/akebia-announces-voice-trial-met-predefined-stopping-criteria-thefly-news
2 · Reply
Noname2022
Noname2022 Jul. 28 at 4:41 PM
$CRMD $DVA $FMS Study showing safety of using Taurolidine lock solution with a Clearguard HD caps… https://www.sciencedirect.com/science/article/pii/S2468024926010144
0 · Reply
Latest News on DVA
DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call

Jul 21, 2026, 5:00 PM EDT - 13 days ago

DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call


DaVita price target raised to $250 from $205 at Truist

2026-07-14T11:50:38.000Z - 20 days ago

DaVita price target raised to $250 from $205 at Truist


DaVita price target raised to $270 from $235 at UBS

2026-07-10T10:20:39.000Z - 24 days ago

DaVita price target raised to $270 from $235 at UBS


DaVita price target raised to $218 from $194 at Barclays

2026-07-08T10:25:50.000Z - 26 days ago

DaVita price target raised to $218 from $194 at Barclays


DaVita price target raised to $201 from $144 at TD Cowen

2026-05-11T14:28:21.000Z - 3 months ago

DaVita price target raised to $201 from $144 at TD Cowen


DaVita price target raised to $205 from $158 at Truist

2026-05-08T11:57:34.000Z - 3 months ago

DaVita price target raised to $205 from $158 at Truist


DaVita price target raised to $235 from $190 at UBS

2026-05-07T13:29:05.000Z - 3 months ago

DaVita price target raised to $235 from $190 at UBS


DaVita price target raised to $194 from $158 at Barclays

2026-05-07T11:44:30.000Z - 3 months ago

DaVita price target raised to $194 from $158 at Barclays


DaVita upgraded to Buy from Hold at Deutsche Bank

2026-05-07T10:41:29.000Z - 3 months ago

DaVita upgraded to Buy from Hold at Deutsche Bank


DaVita rises 19.6%

2026-05-07T03:38:03.000Z - 3 months ago

DaVita rises 19.6%


DaVita Earnings Call Transcript: Q1 2026

May 5, 2026, 5:00 PM EDT - 3 months ago

DaVita Earnings Call Transcript: Q1 2026


DaVita Earnings release: Q1 2026

May 5, 2026, 5:00 PM EDT - 3 months ago

DaVita Earnings release: Q1 2026


DaVita Quarterly report: Q1 2026

May 5, 2026, 5:00 PM EDT - 3 months ago

DaVita Quarterly report: Q1 2026


DaVita reports Q1 EPS $2.87, consensus $2.33

2026-05-05T20:28:38.000Z - 3 months ago

DaVita reports Q1 EPS $2.87, consensus $2.33


DaVita sees FY26 adjusted EPS $14.10-$15.20, consensus $14.12

2026-05-05T20:23:26.000Z - 3 months ago

DaVita sees FY26 adjusted EPS $14.10-$15.20, consensus $14.12


DaVita Inc. 1st Quarter 2026 Results

May 5, 2026, 4:05 PM EDT - 3 months ago

DaVita Inc. 1st Quarter 2026 Results


Honeywell Announces Board of Directors for Honeywell Aerospace

Apr 28, 2026, 7:00 AM EDT - 3 months ago

Honeywell Announces Board of Directors for Honeywell Aerospace

HON


DaVita Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 3 months ago

DaVita Proxy statement: Proxy filing


DaVita Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 3 months ago

DaVita Proxy statement: Proxy filing


DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call

Apr 20, 2026, 2:06 PM EDT - 3 months ago

DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call


DaVita Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:50 AM EST - 5 months ago

DaVita Transcript: TD Cowen 46th Annual Health Care Conference


DaVita price target raised to $158 from $128 at Truist

2026-02-05T15:05:21.000Z - 6 months ago

DaVita price target raised to $158 from $128 at Truist


DaVita price target raised to $144 from $133 at TD Cowen

2026-02-04T13:50:41.000Z - 6 months ago

DaVita price target raised to $144 from $133 at TD Cowen


DaVita price target raised to $190 from $186 at UBS

2026-02-04T11:36:08.000Z - 6 months ago

DaVita price target raised to $190 from $186 at UBS


TER Quarterly Sales Top $1B, DVA & PEP Beat Earnings

Feb 3, 2026, 11:00 AM EST - 6 months ago

TER Quarterly Sales Top $1B, DVA & PEP Beat Earnings

PEP TER


DaVita Earnings Call Transcript: Q4 2025

Feb 2, 2026, 5:00 PM EST - 6 months ago

DaVita Earnings Call Transcript: Q4 2025


DaVita Annual report: Q4 2025

Feb 2, 2026, 5:00 PM EST - 6 months ago

DaVita Annual report: Q4 2025


DaVita Earnings release: Q4 2025

Feb 2, 2026, 5:00 PM EST - 6 months ago

DaVita Earnings release: Q4 2025


DaVita Annual report: Q4 2025

Feb 2, 2026, 5:00 PM EST - 6 months ago

DaVita Annual report: Q4 2025


DaVita Inc. 4th Quarter 2025 Results

Feb 2, 2026, 4:05 PM EST - 6 months ago

DaVita Inc. 4th Quarter 2025 Results


DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call

Jan 21, 2026, 10:00 AM EST - 6 months ago

DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call


DaVita Names New Leaders to Accelerate Care Transformation

Dec 11, 2025, 8:00 AM EST - 8 months ago

DaVita Names New Leaders to Accelerate Care Transformation


DaVita Transcript: Wolfe Research Healthcare Conference 2025

Nov 17, 2025, 11:20 AM EST - 9 months ago

DaVita Transcript: Wolfe Research Healthcare Conference 2025


DaVita Inc. to Participate in Fireside Chat with Wolfe Research

Nov 14, 2025, 4:16 PM EST - 9 months ago

DaVita Inc. to Participate in Fireside Chat with Wolfe Research


DaVita Earnings Call Transcript: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 9 months ago

DaVita Earnings Call Transcript: Q3 2025


DaVita Quarterly report: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 9 months ago

DaVita Quarterly report: Q3 2025


DaVita Earnings release: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 9 months ago

DaVita Earnings release: Q3 2025


DaVita Inc. 3rd Quarter 2025 Results

Oct 29, 2025, 4:05 PM EDT - 9 months ago

DaVita Inc. 3rd Quarter 2025 Results


DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call

Oct 13, 2025, 2:00 PM EDT - 10 months ago

DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call


DaVita Earnings Call Transcript: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 1 year ago

DaVita Earnings Call Transcript: Q2 2025


DaVita Quarterly report: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 1 year ago

DaVita Quarterly report: Q2 2025


DaVita Earnings release: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 1 year ago

DaVita Earnings release: Q2 2025


DaVita Inc. 2nd Quarter 2025 Results

Aug 5, 2025, 4:05 PM EDT - 1 year ago

DaVita Inc. 2nd Quarter 2025 Results


DaVita Inc. Announces Offering of $750 Million Senior Notes

May 20, 2025, 8:51 AM EDT - 1 year ago

DaVita Inc. Announces Offering of $750 Million Senior Notes


DaVita Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

DaVita Earnings Call Transcript: Q1 2025


DaVita Quarterly report: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

DaVita Quarterly report: Q1 2025


DaVita Earnings release: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

DaVita Earnings release: Q1 2025


DaVita First-Quarter 2025 Financial Results: Just the Numbers

May 12, 2025, 4:51 PM EDT - 1 year ago

DaVita First-Quarter 2025 Financial Results: Just the Numbers


DaVita Inc. 1st Quarter 2025 Results

May 12, 2025, 4:05 PM EDT - 1 year ago

DaVita Inc. 1st Quarter 2025 Results


DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

Apr 30, 2025, 11:00 AM EDT - 1 year ago

DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call


DaVita Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

DaVita Proxy statement: Proxy Filing


DaVita Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

DaVita Proxy statement: Proxy Filing


DaVita Says Ransomware Attack Affecting Some Operations

Apr 14, 2025, 7:35 AM EDT - 1 year ago

DaVita Says Ransomware Attack Affecting Some Operations


Dialysis firm DaVita hit by ransomware attack

Apr 14, 2025, 7:33 AM EDT - 1 year ago

Dialysis firm DaVita hit by ransomware attack


Berkshire Hathaway sells another 750,000 DaVita shares

Feb 19, 2025, 8:05 PM EST - 1 year ago

Berkshire Hathaway sells another 750,000 DaVita shares


Berkshire sells some DaVita shares, cuts stake to 45%

Feb 13, 2025, 8:13 PM EST - 1 year ago

Berkshire sells some DaVita shares, cuts stake to 45%


DaVita forecasts 2025 profit below estimates, shares plummet

Feb 13, 2025, 6:07 PM EST - 1 year ago

DaVita forecasts 2025 profit below estimates, shares plummet


DaVita Earnings Call Transcript: Q4 2024

Feb 13, 2025, 5:00 PM EST - 1 year ago

DaVita Earnings Call Transcript: Q4 2024


DaVita Annual report: Q4 2024

Feb 13, 2025, 5:00 PM EST - 1 year ago

DaVita Annual report: Q4 2024


DaVita Earnings release: Q4 2024

Feb 13, 2025, 5:00 PM EST - 1 year ago

DaVita Earnings release: Q4 2024


DaVita Inc. 4th Quarter 2024 Results

Feb 13, 2025, 4:05 PM EST - 1 year ago

DaVita Inc. 4th Quarter 2024 Results


DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call

Jan 30, 2025, 11:55 AM EST - 1 year ago

DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call


MikeyMcDermott
MikeyMcDermott Aug. 3 at 11:53 PM
$DVA crazy strong chart. those monthly bars straight up and new ATHs. can it continue after earnings?
0 · Reply
Noname2022
Noname2022 Aug. 3 at 9:09 PM
$CRMD $DVA $FMS $AKBA https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q2/FME_Q2_2026_Analyst_Presentation.pdf
1 · Reply
Noname2022
Noname2022 Aug. 3 at 8:28 PM
0 · Reply
k3vl4r
k3vl4r Aug. 3 at 4:45 PM
$DAVITA is about to get a surprise: kidney stone demand could be overheated before earnings. Thoughts? https://app.k3vl4r.com/blog/dva-davita-s-kidney-stones-why-the-dialysis-renaissance-might-be-priced?utm_source=social&utm_medium=social&utm_campaign=blog_publish $DVA #stocks #investing
0 · Reply
MaverikIT
MaverikIT Aug. 3 at 2:08 PM
$DVA +5.44 - do the give da --- to gp-l1 ? @trader365 @howardlindzon
0 · Reply
Noname2022
Noname2022 Aug. 2 at 1:06 PM
$CRMD $ICUI $DVA $FMS Clearguard HD: guessing DVA contract & best guess at access trends based on their marketing data (Fresenius uses both Clearguard HD & Defencath!) On the Q2 2024 call, ICU Medical said it had: “recently signed a multi-year committed agreement with a leading U.S. operator of dialysis clinics” Management said the agreement would expand its evidence base and help attract other dialysis operators. https://stockanalysis.com/stocks/icui/transcripts/192237-q2-2024/
0 · Reply
SparkyReturns
SparkyReturns Jul. 31 at 2:41 AM
$ICU I wonder how many hospitals are familiar with the Seastar SCD device and some affiliated doctors even trained with it, but are holding out until the SAVE registry goes away soon? For example, they are using the adult SCD at the Ronald Reagan Hospital in LA at UCLA, but the 18 bed pediatric wing is not in the SCD-PED study. However, if the SAVE registry requirements are dropped, will Ron Reagan UCLA Pediatric order 5 or 10 treatments so they have them on hand? If the FDA says it works, would it not be medical negligence not to use the new standard of care on a pediatric patient with AKI/Sepsis? I know the answer to that, and I wouldn't want to be that hospital if they didn't order the SCD-PED like stat. I predict there are 5-10 pediatric hospitals in this situation where if the SAVE Registry is dropped, we could have a flood of 25-100 orders overnight at $18,000 per treatment, or an extra $500K-$2M before we know it. GL! $FMS $DVA $BAX
4 · Reply
MaverikIT
MaverikIT Jul. 29 at 2:48 PM
@howardlindzon @Jblack500 @cynicaloptimist @BustaCapital @IsabellaDC @WAJeff @No_Face_character $DVA waving to another 52wk$ earlier
0 · Reply
Noname2022
Noname2022 Jul. 28 at 5:18 PM
$AKBA $DVA “There was no statistically significant difference between mortality rates with Vafseo versus ESA.” https://www.tipranks.com/news/the-fly/akebia-announces-voice-trial-met-predefined-stopping-criteria-thefly-news
2 · Reply
Noname2022
Noname2022 Jul. 28 at 4:41 PM
$CRMD $DVA $FMS Study showing safety of using Taurolidine lock solution with a Clearguard HD caps… https://www.sciencedirect.com/science/article/pii/S2468024926010144
0 · Reply
Noname2022
Noname2022 Jul. 27 at 7:52 PM
$CRMD $DVA $FMS $ICUI The actual poster of Clearguard HD being implemented at Davita system wide in 2019 note 34% reduction system wide… https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3442083
1 · Reply
MaverikIT
MaverikIT Jul. 27 at 2:27 PM
Yo $SPCX why NOT try $DVA ? or $SPCG
1 · Reply
MaverikIT
MaverikIT Jul. 27 at 2:25 PM
@howardlindzon @Stocktwits $DVA do they care about GP-L1 $LLY $NVO ?
0 · Reply
MaverikIT
MaverikIT Jul. 27 at 2:23 PM
$ISRG +16.68 - not bad $DVA +2.64 - eyeing 52wk$ again
1 · Reply
Noname2022
Noname2022 Jul. 26 at 2:03 AM
$CRMD $DVA “DefenCath® demonstrated a 72% reduction in CRBSI and 70% reduction in hospitalizations secondary to CRBSI” https://cormedix.com/cormedix-therapeutics-announces-positive-data-from-ongoing-real-world-evidence-study-of-defencath/
0 · Reply
Noname2022
Noname2022 Jul. 25 at 2:53 PM
$DVA $CRMD My read: the clinical case for DefenCath is increasingly settled. Getting DaVita on board now appears to be mostly about price, contract terms, and rollout scope. Source: RBC investor call
4 · Reply
howardlindzon
howardlindzon Jul. 23 at 11:32 PM
$DVA everybody yapping about $TSLA meanwhile fat americans been the easiest quietest trend … missed it too.
0 · Reply
MaverikIT
MaverikIT Jul. 23 at 3:25 PM
@Stocktwits @howardlindzon @tctranfo $DVA
1 · Reply
DollarFlipper
DollarFlipper Jul. 22 at 7:30 PM
$BSX $DVA was like this when i bought around 110. Suprise er catapult to 130, sold at 150. Now look at it and buffet trimmed. Here's to hope he bought bsx.
0 · Reply
Noname2022
Noname2022 Jul. 22 at 3:17 AM
$CRMD $DVA $FMS “Additional data from another customer, a mid-sized dialysis operator, showed a 97% reduction in CRBSIs following a broad implementation of DefenCath” AKA most likely innovative renal care (IRC) imho https://www.dpcedcenter.org/wp-content/uploads/2026/06/KIDNEY-CITIZEN-23-Digital.pdf
1 · Reply
WAJeff
WAJeff Jul. 17 at 2:52 AM
Me? I haven’t been affected. My account is 80% $AAPL, 10% $XLF, 10% $DVA 😂
1 · Reply
Noname2022
Noname2022 Jul. 17 at 1:53 AM
$DVA $CRMD Interesting PR from 10 years ago, before Clearguard HD… https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cormedix-inc.-announces-publication-of-new-pharmacoeconomic-data-demon-440113
1 · Reply